Quarterly report pursuant to Section 13 or 15(d)

Intangible Asset (Details Narrative)

v3.10.0.1
Intangible Asset (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2017
Capitalized cost     $ 3,037,147 $ 3,037,147  
Business combination of tax basis     1,782 $ 1,782  
Number of shares acquired in exchange for common stock   31,745,242   2,090,301  
Precentage of issued and outstanding common stock diluted basis   90.00%      
Proceeds from common stock       $ 2,856,073
Amortization expense     197,124 $ 222,559
Weighted average amortization period for intangible asset       14 years  
Future amortization expense, twelve months     788,495 $ 788,495  
Future amortization expense, year two     788,495 788,495  
Future amortization expense, year three     788,495 788,495  
Future amortization expense, year four     788,495 788,495  
Future amortization expense, year five     788,495 788,495  
Subscription Receivable [Member]          
Proceeds from royalty receivable       8,000,000  
CoNCERT Pharmaceuticals, Inc [Member]          
Capitalized cost     11,038,929 11,038,929  
Transaction costs     $ 1,782 $ 1,782  
Option exercised in exchange for common stock $ 8,000,000        
Number of shares acquired in exchange for common stock 2,090,301        
Percentage of common stock holdings 6.58%        
Precentage of issued and outstanding common stock diluted basis 5.93%        
Percentage of royalty 15.00%        
Proceeds from royalty receivable $ 8,000,000        
Proceeds from common stock $ 8,000,000